ClinConnect ClinConnect Logo
Search / Trial NCT06992297

Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum Malaria

Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · May 27, 2025

Trial Information

Current as of June 27, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the long-term effects of severe Plasmodium falciparum malaria, a serious form of malaria that can lead to significant health problems. Researchers want to learn more about the lasting issues that some patients experience after being treated for this illness, especially looking at neurological problems (like issues with thinking and memory) and other complications such as kidney failure. The study aims to compare patients who had neurological symptoms with those who did not, and it hopes to improve follow-up care for patients after they leave the hospital.

To participate in this trial, you need to be an adult (18 years or older) who was diagnosed with severe malaria and received treatment at a specific hospital between 2018 and 2024. You must have been treated with a specific medication called Artesunate IV. It's important to note that people with certain pre-existing health conditions, such as advanced neurodegenerative diseases, or those who cannot understand French, will not be eligible. Participants will have the opportunity to share their experiences, and the findings from this study could help improve care for future malaria patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female over 18 years of age
  • Have been diagnosed with severe malaria according to WHO criteria and have been treated between 1/1/2018 and 321/12/2024 at the AP-HM
  • Have been treated with Artesunate IV (MALACEF®) (at least one dose)
  • Patient who has received information about the study and has not expressed opposition
  • Patient benefiting or entitled to benefit from a social security scheme
  • Exclusion Criteria:
  • Patients with advanced neurodegenerative pathology pre-existing the malaria attack
  • Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code (minor patients, patients of legal age under guardianship, curatorship or safeguard of justice, patients deprived of their liberty, pregnant or breast-feeding women),
  • Persons who do not understand French

About Assistance Publique Hopitaux De Marseille

Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.

Locations

Marseille, , France

Patients applied

0 patients applied

Trial Officials

Francois CREMIEUX

Study Director

APHM

Coralie L'OLLIVIER, doctor

Principal Investigator

APHM

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported